<DOC>
	<DOCNO>NCT00704431</DOCNO>
	<brief_summary>Subjects receive first dose darapladib clinical research unit ( CRU ) , remain 9 day dose occur home . Subjects record adverse event throughout dose period paper diary . Subjects return CRU 10-14 day last dose darapladib follow-up visit . The total study duration subject include screening , treatment follow-up period approximately 4 week .</brief_summary>
	<brief_title>A Study With Darapladib Collect Tolerability Information</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test ECG . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit . Body weight &gt; = 50 kg BMI within range 19 30 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . History drug abuse . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History anaphylaxis , anaphylactoid reaction severe allergic response . History adult asthma manifest bronchospasm past 6 month currently take regular antiasthmatic medication . Currently receive oral injectable strong CYP3A4 inhibitor ( ) . Consumption grapefruit grapefruit juice within 7 day prior first dose study medication . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum hCG test screening . Lactating female . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>SB-480848</keyword>
	<keyword>darapladib</keyword>
	<keyword>tolerability</keyword>
</DOC>